Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 6, 03 August 2023
Open
Access | Article
Liquid biopsy of circulating tumor DNA in cerebrospinal fluid for early diagnosis of brain malignancies: A review
* Author to whom correspondence should be addressed.
Abstract
Brain cancer is the most aggressive intracranial disease: once diagnosed, 70% of patients will not survive. Early and accurate diagnosis is essential to improving the survival rate of diagnosed patients. Currently, imaging scans and pathological biopsies are mainly relied on to confirm the diagnosis of brain tumors. However, imaging scans do not confirm the diagnosis or tumor grade, nor do assess response and monitor treatment effect. Similarly, pathological biopsies are highly invasive and difficult to repeat. To address these limitations, the field has proposed the use of cerebrospinal fluid (CSF) as a liquid biopsy method to detect circulating tumor DNA (ctDNA). This review focuses on how liquid biopsy of CSF ctDNA can facilitate and complement the clinical care of patients with brain tumors. Relevant reviews in the past five years show that ctDNA is highly expressed and its content in CSF is higher than that in plasma. By sequencing the ctDNA of CSF, the diagnosis and prognosis information of brain tumors can be obtained, the best treatment method can be selected, the treatment response can be monitored, and the tumor evolution can be tracked. Because ctDNA detection is still in the research stage and lacks standardized technology, its effectiveness and practicality require further investigation before they can be used in clinical practice.
Keywords
brain malignancies, circulating Tumour DNA, liquid biopsies, early diagnosis, cerebrospina fluid
References
1. Latif, G., Butt, M. M., Khan, A. H., Butt, O., & Iskandar, D. A. Multiclass brain Glioma tumor classification using block-based 3D Wavelet features of MR images. In 2017 4th International Conference on Electrical and Electronic Engineering (ICEEE) (pp. 333-337). IEEE. (2017, April).
2. Neetu Mittal and Satyam Tayal. Advance computer analysis of magnetic resonance imaging (mri) for early brain tumor detection. International Journal of Neuroscience, 0(0):1–16, PMID: 32241208. (2020).
3. Sarah Ali Abdelaziz Ismael, Ammar Mohammed, and Hesham Hefny. An enhanced deep learning approach for brain cancer mri images classification using residual networks. Artificial Intelligence in Medicine, 102:101779, (2020).
4. A. Al-Badarneh, H. Najadat, and A. M. Alraziqi. A classifier to detect tumor disease inmri brain images. In2012 IEEE/ACM International Conference on Advances in Social Networks Analysis and Mining, pages 784–787, (2012).
5. Kazunori Arita, Makiko Miwa, Manoj Bohara, F. M. Moinuddin, and Koji Yoshimoto. Precision of preoperative diagnosis in patients with brain tumor — a prospective study based on “top three list” of differential diagnosis for 1061 patients. Surgical Neurology International, 11:55, (2020).
6. Bettegowda C, Sausen M, Leary R.J,etal. Detection of circulating tumor DNA in early and late-stage human malignancies. Sci Transl Med, 6:224ra24 (2014).
7. Ghersi-Egea JF, Strazielle N, Catala M,etal. Molecular anatomy and functions of the choroidal blood-cerebrospinal fluid barrier in health and disease. ActaNeuropathol; 135:337–361. (2018).
8. Miller, A. M., Shah, R. H., Pentsova, E. I., Pourmaleki, M., Briggs, S., Distefano, N.et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature565, 654–658 (2019).
9. Killock, D. C. S. F. DNA provides a snapshot of the glioma genome. Nat. Rev. Clin.Oncol.16, 143–143 (2019).
10. Schmitt-Gra ̈ff A, Hummel M, Anagnostopoulos I,etal. Primary brain lymphoma in acquired immunodeficiency syndrome. Immunophenotype and molecular pathologic characterization in stereotactic biopsy, autopsy and cerebrospinal fluid cytology. Pathology; 16:75–80. (1995).
11. Rhodes CH, Honsinger C, Sorenson GD. PCR-detection of tumor-derivedp53 DNA in cerebrospinal fluid. Am J Clin Pathol; 103:404–408. (1995).
12. Swinkels DW, de Kok JB, Hanselaar A,etal. Early detection of leptomeningeal metastasis by PCR examination of tumor-derived K-ras DNA in cerebrospinal fluid. Clin Chem; 46:132– 133. (2000).
13. Shi W, Lv C, Qi J,etal. Prognostic value of free DNA quantification in serum and cerebrospinal fluid in glioma patients. J Mol Neurosci; 46:470–475. (2012).
14. Yang H, Cai L, Zhang Y,etal. Sensitive detection of EGFR mutations incerebrospinal fluid from lung adenocarcinoma patients with brain metastases. J Mol Diagn; 16:558–563. (2014).
15. Touat M, Duran-Pen ̃a A, Alentorn A,etal.Emerging circulating biomarkers in glioblastoma: promises and challenges. Expert Rev Mol Diagn;15:1311–1323. (2015).
16. De Mattos-Arruda L, Mayor R, Ng CKY,etal. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun; 6:8839. (2015).
17. Pan W, Gu W, Nagpal S,etal. Brain tumor mutations detected in cerebralspinal fluid. Clin Chem; 61:514 – 522. (2015).
18. Wang Y, Springer S, Zhang M,etal. Detection of tumor-derived DNA incerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci U S A; 112:9704–9709. (2015).
19. Pentsova EI, Shah RH, Tang J,etal.Evaluating cancer of the central nervoussystem through next-generation sequencing of cerebrospinal fluid. J ClinOncol; 34:2404–2415. (2016).
20. Martı ́nez-Ricarte F, Mayor R, Martı ́nez-Sa ́ez E,etal. Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumor DNA from cerebrospinal fluid. Clin Cancer Res; 24:2812–2819 (2018).
21. Mouliere F, Mair R, Chandrananda D,etal. Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients. EMBO Mol Med; 10:e9323. (2018)
22. Miller AM, Shah RH, Pentsova EI,etal.Tracking tumour evolution in gliomathrough liquid biopsies of cerebrospinal fluid. Nature; 565:654–658. (2019).
23. Seoane J, De Mattos-Arruda L, Le Rhun E,etal.Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. Ann Oncol; 30:211–218. Revision of the implications of the study of CSF ctDNA on primary and metastatic brain malignancies. (2019).
24. Le Rhun E, Seoane J, Salzet M,etal.Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. Cancer Lett; 480:24–28 (2020).
25. De Mattos-Arruda L, Mayor R, Ng CKY, etal. Cerebrospinal fluid derived circulating tumour DNA better represents the genomic alterations of braintumours than plasma. Nat Commun; 6:8839. (2015).
26. Pentsova EI, Shah RH, Tang J, etal. Evaluating cancer of the central nervoussystem through next-generation sequencing of cerebrospinal fluid. J ClinOncol; 34:2404–2415. (2016).
27. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer;11:426–437. (2011).
28. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med;368:1199–1209. (2013).
29. Wang J, Bettegowda C. Applications of DNA-based liquid biopsyfor central nervous system neoplasms. J Mol Diagn;19:24–34. (2017). doi:10.1016/j.jmoldx.2016.08.007
30. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med.;14:985–990. (2008). doi:10.1038/nm.1789
31. Diehl, F.et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med.14, 985–990 (2008).
32. Li J, Han X, Yu X, et al. Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. J Exp Clin Cancer Res.; 37:213. (2018) doi:10.1186/s13046-018-0893-1
33. Diaz LA Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol; 32:579–586. (2014). doi:10.1200/JCO.2012.45.2011
34. Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., ... & Diaz Jr, L. A. Circulating mutant DNA to assess tumor dynamics. Nature medicine, 14(9), 985-990. (2008).
35. Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature; 486:537–40. (2012).
36. Sottoriva A, Spiteri I, Piccirillo SG,etal. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A; 110:4009–4014. (2013).
37. Brat DJ, Verhaak RG, Aldape KD,etal. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med; 372:2481–2498. (2015).
38. Ceccarelli M, Barthel FP, Malta TM,etal. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell; 164:550–563. (2016).
39. Capper, D., Jones, D. T., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D., ... & Pfister, S. M. DNA methylation-based classification of central nervous system tumours. Nature, 555(7697), 469-474. (2018).
40. Martı ́nez-Ricarte F, Mayor R, Martı ́nez-Sa ́ez E,etal. Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumor DNA from cerebrospinal fluid. Clin Cancer Res; 24:2812 – 2819. (2018).
41. Azad, T. D., Jin, M. C., Bernhardt, L. J., & Bettegowda, C. Liquid biopsy for pediatric diffuse midline glioma: A review of circulating tumor DNA and cerebrospinal fluid tumor DNA. Neurosurgical focus, 48(1), E9. (2020).
42. Juratli, T. A., Stasik, S., Zolal, A., Schuster, C., Richter, S., Daubner, D., ... & Thiede, C. TERT Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with IDH Wild-Type Glioblastomas: A Pilot Prospective StudyTERT Promoter Mutations in Glioblastoma Cell-Free Tumor DNA. Clinical Cancer Research, 24(21), 5282-5291. (2018).
43. Miller, A. M., Shah, R. H., Pentsova, E. I., Pourmaleki, M., Briggs, S., Distefano, N., ... & Mellinghoff, I. K. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature, 565(7741), 654-658. (2019).
44. Bobillo, S., Crespo, M., Escudero, L., Mayor, R., Raheja, P., Carpio, C., ... & Seoane, J. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica, 106(2), 513. (2021).
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the International Conference on Modern Medicine and Global Health (ICMMGH 2023)
- ISBN (Print)
- 978-1-915371-65-2
- ISBN (Online)
- 978-1-915371-66-9
- Published Date
- 03 August 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/6/20230192
- Copyright
- 03 August 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited